Clinical Trial Detail

NCT ID NCT03694522
Title A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT) (FIGHT)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Five Prime Therapeutics, Inc.
Indications

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin

Fluorouracil + Leucovorin + Oxaliplatin

Age Groups: senior adult

Additional content available in CKB BOOST